Arunesh Verma Joins Fresenius Kabi USA as President
10 Julio 2024 - 10:30AM
Business Wire
Verma succeeds John Ducker who will retire
after 35 years with Fresenius
Fresenius Kabi announced today that Arunesh Verma has joined the
company as president of Fresenius Kabi USA and a member of the
company’s global Executive Leadership Team, reporting to Pierluigi
Antonelli, CEO of Fresenius Kabi.
Verma is responsible for the commercial operations of Fresenius
Kabi in the United States. He succeeds John Ducker, who is retiring
after a highly successful 35-year career with Fresenius Kabi.
“I am very pleased to welcome Arunesh Verma to our company at a
time when we are successfully executing our #Vision2026
transformation in line with #FutureFresenius, strengthening our
commercial operations, and bringing online advanced new U.S.
manufacturing capabilities – all designed to support U.S.
caregivers,” said Pierluigi Antonelli. “At the same time, I want to
thank John Ducker for his outstanding leadership and achievement
over 35 years. His contributions have shaped our company’s growth
and reputation in the U.S. in profound ways.”
Fresenius Kabi, an operating company of Fresenius, is a global
health care leader that specializes in medicines and technologies
for infusion, transfusion and clinical nutrition. In the U.S.,
Fresenius Kabi plays an essential role in patient care as a leading
developer and manufacturer of injectable medicines and biosimilars
used in hospitals and other sites of care. The company is also a
leader in clinical nutrition and medical technologies that infuse
medicines into patients, that collect and process human blood, and
that enable cell and gene therapies.
“I am thrilled to join Fresenius Kabi, a highly respected global
leader with an outstanding reputation in the U.S. and deep roots in
health care worldwide,” Verma said. “Fresenius Kabi specializes in
putting essential medicines and technologies in the hands of people
who care for patients – and this is a purpose to which I have
devoted my career of more than 22 years.”
Verma joins Fresenius Kabi from Cipla, a global pharmaceutical
company, where he was CEO of Cipla North America and a member of
the company’s global Management Council. He started his career as a
medical sales representative with Novartis and has held roles of
increasing responsibility at Cipla, Torrent Pharma, Sandoz and Dr.
Reddy’s Laboratories, where he has led pharmaceutical businesses
and functions in the U.S., Central America, Australia and Asia.
Verma holds a master’s degree in business management, marketing and
communications from Symbiosis Institute of Business Management and
a bachelor’s degree in pharmaceutical sciences, pharmacology and
pharmaceutics from the University of Mumbai.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com/us) is a global health
care company that specializes in injectable medicines, biosimilars,
and technologies for infusion, transfusion, and clinical nutrition.
The company’s products and services are used to help care for
patients with critical and chronic conditions. The company’s U.S.
headquarters is in Lake Zurich, Illinois. The company’s global
headquarters is in Bad Homburg, Germany. To learn about U.S. career
opportunities at Fresenius Kabi USA, visit us at
www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240710800639/en/
Matt Kuhn (847) 220-3033 matt.kuhn@fresenius-kabi.com